Purivitae Ventures

Purivitae focuses on seed and Series A rounds, entering at the point where academic research achieves proof-of-concept data and requires initial capital to fund regulatory pathways and early clinical validation. The firm does not publicly participate in late-stage crossover rounds or public-market equities.

Purivitae Ventures invests exclusively in human health. The firm does not deploy capital into generalist software, consumer internet, fintech, or industrial technology. Within healthcare, its concentration on early-stage diagnostics and therapeutics means it typically avoids healthcare services roll-ups, revenue-cycle management, and hospital operations.

The firm leverages the biomedical research networks of Midwestern academic institutions, including relationships with university technology transfer offices. This sourcing model — proximity to research labs rather than pitch competitions or accelerator demo days — produces a pipeline weighted toward deep-tech life-science companies with intellectual property rooted in institutional science.

Purivitae operates as a traditional venture capital partnership raising capital from external limited partners. It is not a single family office, corporate venture arm, or foundation-linked investment vehicle. Fund structures, LP composition, and capital-raising history are not publicly disclosed.

Purivitae co-invests alongside regional angel networks and larger life-science venture funds, often acting as the first institutional capital into a university spin-out. Its small fund size and early entry point make it a syndicate partner rather than a lead investor on larger rounds.